Patents Assigned to Cytograft Tissue Engineering, Inc.
  • Publication number: 20150088247
    Abstract: A single-layer tissue sheet having a puncture strength of 2 kgf to 6 kgf. A valve, such as a heart valve, made of one or more leaflets formed from a single-layer tissue sheet. A method of making a tissue sheet having a puncture strength of 2 kgf to 5 kgf. The ultra-strong tissue sheets described herein have very long culture times, such as in excess of 20 weeks. Valves that comprise one or more leaflets made from the ultra-strong tissue sheets described herein may be delivered via trans-cathete aortic valve implantation.
    Type: Application
    Filed: March 25, 2013
    Publication date: March 26, 2015
    Applicant: Cytograft Tissue Engineering, Inc.
    Inventors: Nicolas L'Heureux, Todd N. McAllister, Nathalie Dusserre
  • Publication number: 20140271454
    Abstract: The present technology provides for a cell-synthesized biological particle, the processes for making a cell-synthesized particle, and a process for assembling such cell-synthesized particles into tissues and organs. The particles are synthesized in culture in vitro by living cells that produce natural extracellular matrix. Multiple particles can be assembled into tissues that have significant void space. The particles or tissues can act as a substrate for additional cell types. The particles or tissues can be further cultured in vitro to achieve favorable cell or extracellular matrix growth, organization or other desired characteristics. The particles or tissues can be devitalized or decellularized. The particles or tissues can be injected or implanted in a human to repair, enhance, or create a secretory, mechanical, or aesthetic function.
    Type: Application
    Filed: April 23, 2012
    Publication date: September 18, 2014
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Nicolas L'Heureux, Todd N McAllister
  • Publication number: 20140081385
    Abstract: The technology described herein generally relates to the field of tissue engineering and treatment of cardiovascular disease by endovascular repair. The technology more particularly relates to devices and methods to produce a tissue-based implant that can be used for abdominal aorta aneurysm, thoracic aorta aneurysm, or other cardiovascular repair.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Sergio A. Garrido, Nicolas L'Heureux
  • Publication number: 20120150092
    Abstract: The invention includes methods and apparatus to deploy a blood vessel conduit via a catheter-based, percutaneous approach. In particular, a prosthetic blood conduit can be introduced around or through an arterial obstruction without requiring open bypass surgery. The technology includes coupling devices for docking the tips of two catheters, one situated inside a blood vessel, the other situated outside the blood vessel wall.
    Type: Application
    Filed: March 17, 2010
    Publication date: June 14, 2012
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Todd N McAllister, Sergio A Garrido, Nicolas L'Heureux
  • Patent number: 8076137
    Abstract: The disclosure provides methods and compositions to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: December 13, 2011
    Assignee: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Publication number: 20100189712
    Abstract: The present technology provides for a cell-synthesized biological thread, processes for making a cell-synthesized thread, and an apparatus for carrying out a process used to engineer the cell-synthesized thread. The thread is produced from living cells in culture and can be grown around the outer surface of a cylindrical bioreactor. The tissue comprising the thread has mechanical and biological properties achieved by altering the climactic conditions, stresses and strains on the tissue and chemical composition that prove beneficial in the medical industry. This process results in a biological thread that has high mechanical strength, decreased immunogenic effect and decreased thrombogenic effect when combined with other tissue. It also results in a product which can be used to create more complex constructs that otherwise could not have been generated. The threads can be used to make sutures, patches, and tubes, for example.
    Type: Application
    Filed: November 19, 2007
    Publication date: July 29, 2010
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Nicolas L'Heureux, Todd N. McAllister
  • Patent number: 7744526
    Abstract: The invention relates to bioreactors having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling for the manufacture of a tissue engineered blood vessel (TEBV). The TEBV is made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: June 29, 2010
    Assignee: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Publication number: 20100040663
    Abstract: The technology described herein generally relates to the field of tissue engineering and treatment of cardiovascular disease by endovascular repair. The technology more particularly relates to devices and methods to produce a tissue-based implant that can be used for abdominal aorta aneurysm, thoracic aorta aneurysm, or other cardiovascular repair.
    Type: Application
    Filed: June 16, 2009
    Publication date: February 18, 2010
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Todd N. McAllister, Sergio A. Garrido, Nicolas L'Heureux
  • Publication number: 20090233356
    Abstract: The disclosure provides methods and compositions to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic.
    Type: Application
    Filed: March 17, 2009
    Publication date: September 17, 2009
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Patent number: 7504258
    Abstract: The disclosure provides methods and composition to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic. The use of tissue manipulation devices further allows for the assembly of complex tissue engineered organs.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: March 17, 2009
    Assignee: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Publication number: 20070178588
    Abstract: The disclosure provides methods and systems for tissue engineering including an apparatus and methods for the growth, maintenance, and use of robust tissue sheets using tissue manipulation devices. The tissue manipulation devices provide a method of anchoring the tissue sheets to the cell culture substrate to promote prolonged maturation and subsequent increased mechanical strength. The tissue manipulation devices also provide a technique to facilitate removal of the sheet from the culture container and subsequent production steps to assemble more complex three dimensional organs from the robust sheet. The tissue manipulation devices also facilitate automated handling of the sheets in the assembly processes. The disclosure provides methods and composition derived from robust human sheets to build tissue engineered blood vessels, heart valves, stents, and endarterectomy patches and the like.
    Type: Application
    Filed: December 14, 2006
    Publication date: August 2, 2007
    Applicant: Cytograft Tissue Engineering, Inc.
    Inventors: Todd McAllister, Nicolas L'Heureux
  • Patent number: 7166464
    Abstract: The disclosure provides methods and systems for tissue engineering including an apparatus and methods for the growth, maintenance, and use of robust tissue sheets using tissue manipulation devices. The tissue manipulation devices provide a method of anchoring the tissue sheets to the cell culture substrate to promote prolonged maturation and subsequent increased mechanical strength. The tissue manipulation devices also provide a technique to facilitate removal of the sheet from the culture container and subsequent production steps to assemble more complex three dimensional organs from the robust sheet. The tissue manipulation devices also facilitate automated handling of the sheets in the assembly processes. The disclosure provides methods and composition derived from robust human sheets to build tissue engineered blood vessels, heart valves, stents, and endarterectomy patches and the like.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: January 23, 2007
    Assignee: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Publication number: 20060286664
    Abstract: The invention relates to bioreactors having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling for the manufacture of a tissue engineered blood vessel (TEBV). The TEBV is made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding.
    Type: Application
    Filed: August 25, 2006
    Publication date: December 21, 2006
    Applicant: CYTOGRAFT TISSUE ENGINEERING, INC.
    Inventors: Todd McAllister, Nicolas L`Heureux
  • Patent number: 7112218
    Abstract: The invention is a tissue engineered blood vessel (TEBV) made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding. The TEBV is made in a bioreactor having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: September 26, 2006
    Assignee: Cytograft Tissue Engineering, Inc.
    Inventors: Todd N. McAllister, Nicolas L'Heureux
  • Publication number: 20020188349
    Abstract: The invention is a tissue engineered blood vessel (TEBV) made from a cultured fibroblast sheet rolled into a multilayer vessel which has sufficient burst strength to withstand physiological blood pressure without the inclusion of smooth muscle cells or synthetic scaffolding. The TEBV is made in a bioreactor having an enclosed chamber, a sheet growth module, a rollable mandrel, and a clamp for holding the sheet to the mandrel for rolling.
    Type: Application
    Filed: August 1, 2002
    Publication date: December 12, 2002
    Applicant: Cytograft Tissue Engineering, Inc., a California Corporation
    Inventors: Todd N. McAllister, Nicolas L'Heureux